respectively showed that administration of anti CTLA-4 between intervals of chemotherapy (8) or after radiotherapy and surgery (10) offered effective multimodal anti-MM therapeutics, successfully boosting the anti-tumor response. Here, CTLA4 is linked to Miyoshi myopathy.